Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
Titel:
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
Auteur:
Banerjee, Susana Moore, Kathleen N Colombo, Nicoletta Scambia, Giovanni Kim, Byoung-Gie Oaknin, Ana Friedlander, Michael Lisyanskaya, Alla Floquet, Anne Leary, Alexandra Sonke, Gabe S Gourley, Charlie Oza, Amit González-Martín, Antonio Aghajanian, Carol Bradley, William H Holmes, Eileen Lowe, Elizabeth S DiSilvestro, Paul